DiObex develops novel products for the treatment of metabolic disorders.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: San Francisco
State: California
Zip:
Country: United States
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2005 | Series A | 3 | $7.1M |
Domain Associates Pequot Capital Sofinnova Investments Domain Associates Pequot Capital Sofinnova Investments |
4/2007 | Series B | 6 | $24M |
Domain Associates Inventages Venture Capital Investment Inc. Mitsui Global Investment Pac-Link Pequot Capital Sofinnova Investments Domain Associates Inventages Venture Capital Investment Inc. Mitsui Global Investment Pac-Link Pequot Capital Sofinnova Investments |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|